期刊档案 · 医学-生物工程与应用微生物
Current opinion in molecular therapeutics
ISSN 1464-8431 · ENGLAND · Bimonthly · 创刊 1999
Current opinion in molecular therapeutics 影响因子 6.1(官网公布),订阅期刊,投稿社区反馈审稿超过 12 周,录用比例一般(社区反馈)。
研究范围
研究范围与定位
Current opinion in molecular therapeutics。按 OpenAlex 近年发文统计,该刊主要发表 Biomedical Ethics and Regulation、Lymphoma Diagnosis and Treatment、Congenital Heart Disease Studies 等主题的论文,这 3 个主题约占 30.8%。(根据 OpenAlex 主题统计与中科院分区数据生成)
A leader in open access publishing, BMC makes scientific knowledge widely available and champions the benefits of open research for all.BMC is committed to supporting the needs of our communities, safeguarding the integrity of the research we publish, and providing a comprehensive forum for sharing scientifically robust findings with the world.An open access pioneer In 2000, BMC (then BioMed Central) made high quality research open to every reader – and in making the open access model sustainable, we changed the world of academic publishing.We have consistently valued rigorous review and were one of the first publishers to have a dedicated research integrity team, building our reputation for publishing high-quality open access research.BMC continues to partner with authors, editors, and reviewers to make research more discoverable, and to develop new approaches to peer review to give authors an efficient, transparent, and fair process. Innovation in publishing - like research itself - never stops. BMC continues to experiment with and develop new approaches to research publishing, to better support researchers and their communities.Our journals and impact BMC has a portfolio of more than 300 peer-reviewed journals, sharing discoveries from research communities across scientific and clinical disciplines.Some of our journals were the very first open access journals in their fields. Now they, and the journals we have launched in the years since, are some of the largest and most cited open access publications in their disciplines.With the support of over 23,000 editors, we’ve helped authors from more than 160 countries share their findings with the world. Together, we empower our research communities to drive meaningful change. Trusted We publish research held to the highest standards of scientific rigor, accessed by 6 million readers each month.1 Supportive In our author survey, 94% agreed that their review process was ‘detailed and informative’ and ‘useful in improving my manuscript’.2 Inclusive BMC welcomes all robust research, from groundbreaking discoveries to articles, data outputs and methodologies that support sound science and reproducibility. Community-focused We have built a loyal and diverse community of editors, reviewers and authors who play a vital role in ensuring a high standard of research integrity. Footnotes Based on Google Analytics site data from 2024.Springer Nature Journal Author Satisfaction survey, 2024.
摘自期刊官网 Aims & Scope
研究方向(LetPub):医学-生物工程与应用微生物
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Biomedical Ethics and RegulationMedicine15.4%
- Lymphoma Diagnosis and TreatmentMedicine7.7%
- Congenital Heart Disease StudiesMedicine7.7%
- HER2/EGFR in Cancer ResearchMedicine7.7%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology7.7%
- Metabolism and Genetic DisordersBiochemistry, Genetics and Molecular Biology7.7%
- Chronic Lymphocytic Leukemia ResearchMedicine7.7%
- Plant Genetic and Mutation StudiesAgricultural and Biological Sciences7.7%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》( 2026年3月发布)未收录
该期刊未被此版本分区表收录。
期刊分区表( 2023年12月旧的升级版)未收录
该期刊未被此版本分区表收录。
数据库收录
收录数据库:暂无记录。
国际期刊预警名单:各版本均未列入LetPub
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子(出版商公布) 2025
- 6.1出版商官网 ·
- h-index
- 2OpenAlex ·
- i10-index
- 0OpenAlex ·
- 两年平均被引
- 0OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
发文规模
- 年下载量(出版商公布) 2025
- 1,100,000出版商官网 ·
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度(社区反馈)
- >12周,或约稿LetPub ·
- 平均录用比例(社区反馈)
- 一般LetPub ·
- 投稿到首次决定
- 9 天出版商官网 ·
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
订阅期刊,文章需订阅或购买阅读,通常不收取版面费。
尚未从任何来源获得费用信息,请以期刊官网为准。
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
征稿中的专刊3 个,按截稿日期
出版商官网官网政策摘录开放获取
- 开放获取 An open access pioneer
In 2000, BMC (then BioMed Central) made high quality research open to every reader – and in making the open access model sustainable, we changed the world of academic publishing. We have consistently valued rigorous review and were one of the first publishers to have a dedicated research integrity team, building our reputation for publishing high-quality open access research. BMC continues to part…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版国家或地区
- ENGLAND
- 出版周期
- Bimonthly
- 创刊年份
- 1999
- ISSN
- 1464-8431
- 官方链接
- 期刊主页 ↗OpenAlex
常见问题
关于 Current opinion in molecular therapeutics 的常见问题
Current opinion in molecular therapeutics 的影响因子是多少?
期刊官网公布的影响因子为 6.1(2025 年度),属期刊自述数据,LetPub 暂无该刊的影响因子记录,h-index 为 2。
Current opinion in molecular therapeutics 的审稿周期多长?
投稿社区反馈的平均审稿速度为超过 12 周,平均录用比例反馈为“一般”。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Current opinion in molecular therapeutics 是开放获取期刊吗?版面费多少?
Current opinion in molecular therapeutics 为订阅期刊。费用信息尚未获得,请以官网为准。
来源与更新
本页事实来自 LetPub、OpenAlex、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-25 归档)。最近更新:。